Skip to content

Trial · Observational

Active, not recruitingPhase not statedRegistry data

Cardiovascular Effects of Parathyroid Hormone Analogues in Chronic Hypoparathyroidism

Short name PaTH CV

Overview

Status
Active, not recruiting
Phase
Phase not stated
Enrollment
210 participants (estimated)
Sponsor
National and Kapodistrian University of Athens · Other
Design
Not stated
Countries
1 country

Greece

Start
1 Apr 2026
Primary completion
1 Apr 2027 (estimated)
Completion
31 Dec 2028 (estimated)
First posted
16 Jul 2026
Last update posted
16 Jul 2026
Conditions
Chronic Hypoparathyroidism

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. Ph –

    PaTH CV

    NCT07707479

    1 Apr 2026 to est. 31 Dec 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this study is to evaluate cardiovascular effects of long-acting parathyroid hormone (PTH) analogues in adults with chronic hypoparathyroidism. The main questions it aims to answer are: * Do patients with hypoparathyroidism have increased arterial stiffness and markers of subclinical cardiovascular injury compared to healthy individuals? * Does treatment with a long-acting PTH analogue improve vascular and cardiac function over time compared to conventional therapy? This is a multi-center study with two parts: a cross-sectional comparison and a 12-month prospective follow-up. Adults with chronic hypoparathyroidism and matched healthy controls will undergo clinical evaluation, vascular measurements, cardiac imaging, and blood tests. In the prospective part, patients that just started long-acting PTH analogue therapy based on their treating physicians choice will be followed for 12 months, with repeat assessments at baseline, 3 months, and 12 months to evaluate changes in cardiovascular markers.

Interventions

  • Arterial stiffness in the aorta by measurement of pulse wave velocityDiagnostic test
  • Central blood pressures and reflected waves in the aortaDiagnostic test
  • Carotid and femoral intima-media thickness (IMT) and number of carotid or femoral plaquesDiagnostic test
  • Imaging of the sublingual microcirculation (GlycoCheck system)Diagnostic test
  • Ankle-brachial index (ABI)Diagnostic test
  • FundoscopyDiagnostic test
  • Cardiac Ultrasonography StudyDiagnostic test
  • Local shear stress in brachial and carotid arteryDiagnostic test
  • Peripheral and aortic office and ambulatory blood pressureDiagnostic test
  • Circulating levels of myocardial biomarkersDiagnostic test
  • Evaluation of Calcium metabolismDiagnostic test

Arms4

  • Other

    Patients with chronic hypoparathyroidism under conventional treatment (disease control)

    20-30 Hypo-PT patients aged ≥18 on conventional HypoPT therapy with any dose of activated vitamin D and calcium and native vitamin D supplements for at least 12 months

  • Other

    Patients with chronic hypoparathyroidism under treatment with palopegteriparatide

    40-50 Hypo-PT patients aged ≥18 treated with Palopegteriparatide (TransCon PTH) for at least 12 months

  • Other

    Healthy controls

    Healthy controls: 170 Healthy controls matched with group 1 and group 2 for age, sex, CVD presence, propensity score, DM2, renal function, BMI and SBP, retrospectively recruited from the Athens Angiometabolic Cohort

  • Other

    Patients with chronic hypoparathyroidism switching from conventional therapy to palopegteriparatide

    20 patients starting treatment with palopegteriparatide, previously on conventional treatment

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Differences between PTH-treated group, disease control group, and healthy controls in carotid-femoral pulse wave velocity (cfPWV)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months

    Registry description

    Differences in carotid-femoral pulse wave velocity (cfPWV) between patients with hypoparathyroidism receiving conventional therapy, patients treated with long-acting PTH analogue (palopegteriparatide/TransCon PTH), and healthy controls. Two different pulse waves are obtained at the same time transcutaneously with the patient in a supine position at 2 sites, at the right common carotid artery and the right femoral artery (i.e. 'carotid-femoral' PWV) by using pressure-sensitive transducers. The distance traveled by the pulse wave is measured over the body surface and calculated by subtracting the carotid (sternal notch from the carotid)-femoral distance as distance/time (m/s) .

Secondary outcomes(20)
  1. Differences between PTH-treated group, disease control group, and healthy controls in central blood pressure

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months

    Registry description

    Assessment of differences in central blood pressure between patients treated with long-acting PTH analogue, disease controls on conventional therapy, and healthy controls. 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour aortic blood pressure will be performed.

  2. Differences between PTH-treated group, disease control group, and healthy controls in peripheral blood pressure

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline, to 3 and 12 months

    Registry description

    Assessment of differences in central blood pressure between patients treated with long-acting PTH analogue, disease controls on conventional therapy, and healthy controls. 24-hour Ambulatory Blood pressure monitoring for measurement of 24 hour peripheral blood pressure will be performed.

  3. Differences between PTH-treated group, disease control group, and healthy controls in carotid intima-media thickness (IMT)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    B-mode ultrasound examination will be performed, using a 14.0 MHz multi-frequency linear array probe attached to a high-resolution ultrasound machine (Vivid 7 Pro, GE Healthcare, USA). All scans are going to be performed by the same operator. Carotid intima-media thickness (ccIMT) will be measured at the distal 1.0 cm of the common carotid proximal to the bifurcation. In each segment 3 measurements of the maximal IMT in the far wall will be averaged, after excluding plaque thickness. The average of the maximal IMT will be used in the analyses. A cutoff value of \>0.9 mm for mean ccIMT will be considered increased. Plaques to carotid are defined as a focal structure that protrudes into the arterial lumen of at least 0.5 mm or 50

  4. Differences between PTH-treated group, disease control group, and healthy controls in sublingual microcirculation parameters (vascular density)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    The probe of a hand-held side-stream darkfield (SDF) videomicroscope (CapiScope HVCS, KK Technology, Honiton, UK) is placed on the sublingual mucosa of the subject, to obtain video recordings of the sublingual microvasculature. Subsequently, an analysis software (the GlycoCheck Measurement System Software Version 5.3.3) selects and analyses SDF images that are of sufficient quality (adequate focus, adequate contrast and limited movement) and automatically calculates the sublingual microcirculation parameters, (vascular density (VD). Measurements will be performed by one user, experienced in performing sublingual measurements with this tool. Measurements will be taken with subjects in supine position with the researcher standing behind the headboard. Volunteers will be asked to swallow any saliva prior to measuring after which the camera will be manually placed and held still in the sublingual region.

  5. Differences between PTH-treated group, disease control group, and healthy controls in fundoscopic vascular findings.

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    A set of colour and black-and-white fundus images photograph per eye will be taken by well-trained ophthalmic photographers: macula-centered images using the handheld Optomed Aurora fundus cameras without pupil dilation. The images obtained with the handheld fundus camera had a field of view of 50° and 5 mega-pixel resolution.

  6. Differences between PTH-treated group, disease control group, and healthy controls in local shear stress in brachial artery.

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    In order to calculate local shear stress in brachial artery, measurements of mean flow velocity in the lumen of these arteries will be needed. These measurements will be obtained, while performing carotid ultrasonography in brachial artery, as previously described. In detail, the form to calculate shear stress is: shear stress (in dyn/cm2 ) = 8×μ× mean flow velocity/resting diameter, where μ is the viscosity of blood which was assumed to be 0.035 dyne s/cm2

  7. Differences between PTH-treated group, disease control group, and healthy controls in N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Circulating biomarkers of myocardial stress and injury will include N-terminal pro-B-type natriuretic peptide (NT-proBNP). Venous blood samples will be collected after standard clinical preparation, processed according to local laboratory procedures, and analyzed in the hospital's certified biochemistry laboratory using automated immunoassays. NT-proBNP will be measured as a marker of myocardial wall stress and reported in pg/mL. Values will be interpreted according to established clinical thresholds. In the non-acute setting, NT-proBNP \<125 pg/mL will be considered within the normal range, whereas values ≥125 pg/mL will be considered elevated and suggestive of increased myocardial stress. For descriptive analyses, higher-risk thresholds may also be reported, including ≥300 pg/mL and age-adjusted categories when appropriate.

  8. Differences between PTH-treated group, disease control group, and healthy controls in high-sensitivity cardiac troponin (hs-cTn).

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    High-sensitivity cardiac troponin will be measured as a marker of myocardial injury and reported in ng/L. Venous blood samples will be collected after standard clinical preparation, processed according to local laboratory procedures, and analyzed in the hospital's certified biochemistry laboratory using automated immunoassays.

  9. Differences between PTH-treated group, disease control group, and healthy controls in serum phosphate

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.

    Registry description

    Serum phosphate will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dL.

  10. Differences between PTH-treated group, disease control group, and healthy controls in albumin-adjusted serum calcium

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.

    Registry description

    Albumin-adjusted serum calcium will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dl

  11. Differences between PTH-treated group, disease control group, and healthy controls in serum magnesium

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.

    Registry description

    Serum magnesium will be measured in certified clinical laboratories using standard clinical procedures and reported in mg/dL.

  12. Differences between PTH-treated group, disease control group, and healthy controls in serum intact parathyroid hormone (PTH)

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.

    Registry description

    Serum intact parathyroid hormone (PTH) will be measured in certified clinical laboratories using standard clinical procedures and reported in pg/mL.

  13. Differences between PTH-treated group, disease control group, and healthy controls in serum 25-hydroxyvitamin D

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline and 12 months.

    Registry description

    Serum 25-hydroxyvitamin D \[25(OH)D\] will be measured in certified clinical laboratories using standard clinical procedures and reported in ng/mL.

  14. Differences between PTH-treated group, disease control group, and healthy controls in left ventricular global longitudinal strain (GLS)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Left ventricular global longitudinal strain (GLS) will be assessed by speckle-tracking transthoracic echocardiography using standard apical views according to current echocardiographic recommendations. GLS will be reported as percentage (%).

  15. Differences between PTH-treated group, disease control group, and healthy controls in left ventricular ejection fraction (LVEF)

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.

    Registry description

    Left ventricular ejection fraction (LVEF) will be measured by transthoracic echocardiography using the biplane Simpson's method and reported as percentage (%).

  16. Differences between PTH-treated group, disease control group, and healthy controls in left ventricular diastolic function (E/E')

    Time frame · For the cross-sectional arm (baseline comparison): At baseline. For the prospective (interventional) endpoint: At baseline, 12 months.

    Registry description

    Left ventricular diastolic function will be evaluated by Doppler and tissue Doppler echocardiography. The E/E' ratio will be calculated using transmitral early diastolic inflow velocity (E) and the mean early diastolic mitral annular velocity (E').

  17. Differences between PTH-treated group, disease control group, and healthy controls in Augmentation Index (AIx)

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Non-invasive estimation of augmentation index (AIx) normalized to a heart rate of 75 bpm using pulse wave analysis (SphygmoCor System). AIx is expressed as a percentage of central aortic pulse pressure.

  18. Differences between PTH-treated group, disease control group, and healthy controls in Central Systolic Blood Pressure

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Central systolic blood pressure measured non-invasively by pulse wave analysis using the SphygmoCor System.

  19. Differences between PTH-treated group, disease control group, and healthy controls in Central Diastolic Blood Pressure

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Central diastolic blood pressure measured non-invasively by pulse wave analysis using the SphygmoCor System.

  20. Differences between PTH-treated group, disease control group, and healthy controls in Time to Reflected Wave

    Time frame · For the cross-sectional (baseline comparison):At baseline For the prospective (interventional) endpoint: From baseline to 12 months

    Registry description

    Non-invasive estimation of aortic pressure waveforms and reflected waves by pulse wave analysis (PWA) will be performed in the Angiology laboratory by the SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery is gently and steadily compressed against the underlying bone, thus flattening it and equalizing circumferential pressures, allowing radial pressure waves to be recorded by a high fidelity micromanometer placed on the tip of a hand - held tonometer the size of a pen (Millar). Optimal recording is obtained if the wrist is bent outward and supported by using a small cushion or the operator's hand. Time to the beginning of the reflected wave, measured in milliseconds by pulse wave analysis using the SphygmoCor System.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: \- Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months. Exclusion Criteria: * Renal Function: CKD Stage 3 or higher (eGFR \< 60 mL/min/1.73 m²) * Uncontrolled Risk Factors: * SBP \> 180/100 mmHg * Uncontrolled endocrine diseases (e.g., hyper- or hypothyroidism, diabetes mellitus type 2 with HbA1c\>7.5%). * Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis) * Documented Atrial Fibrillation (ECG) * Contraindication to long acting PTH analogue as per product labeling

PepBank is a research reference. Talk to a doctor before you use any peptide.